DelveInsight’s “Spinal Cord Injury Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Spinal Cord Injury pipeline landscape. It covers the Spinal Cord Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Spinal Cord Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Spinal Cord Injury Pipeline? @ https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight

Key Takeaways from the Spinal Cord Injury Pipeline Report

• On June 04, 2026- Northwell Health initiated a study is to measure the tolerability and preliminary efficacy of a drug, galantamine, to treat metabolic syndrome (MetS) by reducing circulating inflammation in people with spinal cord injury (SCI). Galantamine is FDA-approved for the treatment of Alzheimer’s disease. Here, the drug is considered experimental for the purposes of this study.
• On June 03, 2026- Reunion Neuroscience Inc. conducted a study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson’s Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
• DelveInsight’s Spinal Cord Injury Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Spinal Cord Injury treatment.
• The leading Spinal Cord Injury Companies, such as EUSOL Biotech Co., Ltd., Kringle Pharma, Mitsubishi Tanabe Pharma Corporation, Lineage Cell Therapeutics, NervGen Pharma, AlaMab Therapeutics, Axonis Therapeutics, NurExone Biologic, and others.
• Promising Spinal Cord Injury Therapies such as Denosumab, Zoledronic acid, Vibegron, Botulinum toxin A, Pregabalin, GW-1000-02, NVC-422, 0.2%, Vardenafil (Levitra, BAY38-9456), and others.

Want to know which companies are leading innovation in Spinal Cord Injury? @ Spinal Cord Injury Clinical Trials Assessment

The Spinal Cord Injury Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Spinal Cord Injury Pipeline Report also highlights the unmet needs with respect to the Spinal Cord Injury.

Spinal Cord Injury Overview

Spinal cord injury is defined as traumatic damage to the spinal cord or nerves at the end of the spinal canal. This affects the conduction of sensory and motor signals across the site of the lesion. Spinal cord injury is a debilitating neurological condition with tremendous socioeconomic impact on affected individuals and the health care system. Spinal cord injury are two types: incomplete and complete injury. Spinal cord injury (SCI) is a serious medical condition that causes functional, psychological and socioeconomic disorder. Patients with SCI experience significant impairments in various aspects of their life.

Spinal Cord Injury Emerging Drugs Profile

• ES-1601: EUSOL Biotech Co., Ltd.

ES135 is a recombinant human acid fibroblast growth factor (rhFGF1) with 135 amino acids. Its indication for spinal cord injury has been investigated in approximately total 300 patients in phase 1, 2 and 3 clinical trials, respectively. Currently, it is being tested in an exploratory clinical trial in patients with carpal tunnel syndrome for new indication of peripheral nerve injury. Currently the drug is in Phase III stage of its development of spinal cord injury.

• MT-3921: Mitsubishi Tanabe Pharma Corporation

DB102 (enzastaurin) Based on the results of fundamental research by Professor Yamashita’s research team, MT-3921 is a humanized anti-RGMa antibody jointly developed by MTPC and Osaka University since 2005. Current research concluded that RGMa is associated with inhibition of neuronal survival and neuroregeneration, involved in the progression of inflammation, and may play a role in neurological diseases including spinal cord injury, stroke, and multiple sclerosis. The data from the preclinical animal studies conducted by Professor Yamashita’s research team and MTPC indicate that treatment with MT-3921 improves locomotor function and promotes neurodegeneration. Currently the drug is in Phase II stage of its development for spinal cord injury.

• NVG-291: NervGen

NVG-291, is an inhibitor of protein tyrosine phosphatase sigma and has the potential as a therapeutic for diseases where there is nerve damage, either as a result of injury, neurodegenerative disease, or other causes. PTPσ inhibition has been evaluated preclinically in models of spinal cord injury, multiple sclerosis, myocardial ischemia, stroke and other diseases using NVG-291-R. NVG-291-R is a close analog to NVG-291 and works via the same target. In the literature, NVG-291-R is commonly referred to as intracellular signaling peptide, or ISP. Currently, the drug is in the Phase I/II stage of its development for the treatment of Chronic Spinal Cord Injury.

If you’re tracking ongoing Spinal Cord Injury Clinical trials, this press release is a must-read @ Spinal Cord Injury Treatment Drugs

The Spinal Cord Injury Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Spinal Cord Injury with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Cord Injury Treatment.
• Spinal Cord Injury Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Spinal Cord Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Cord Injury market.

Spinal Cord Injury Companies

EUSOL Biotech Co., Ltd., Kringle Pharma, Mitsubishi Tanabe Pharma Corporation, Lineage Cell Therapeutics, NervGen Pharma, AlaMab Therapeutics, Axonis Therapeutics, NurExone Biologic and others.

Spinal Cord Injury Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Spinal Cord Injury Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the Spinal Cord Injury Pipeline Report @ Spinal Cord Injury Market Drivers and Barriers, and Future Perspectives

Scope of the Spinal Cord Injury Pipeline Report

• Coverage- Global
• Spinal Cord Injury Companies- EUSOL Biotech Co., Ltd., Kringle Pharma, Mitsubishi Tanabe Pharma Corporation, Lineage Cell Therapeutics, NervGen Pharma, AlaMab Therapeutics, Axonis Therapeutics, NurExone Biologic and others.
• Spinal Cord Injury Therapies- Denosumab, Zoledronic acid, Vibegron, Botulinum toxin A, Pregabalin, GW-1000-02, NVC-422, 0.2%, Vardenafil (Levitra, BAY38-9456) and others.
• Spinal Cord Injury Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Spinal Cord Injury Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Spinal Cord Injury Treatment landscape in this detailed analysis @ Spinal Cord Injury Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Spinal Cord Injury: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Spinal Cord Injury – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. ES-1601: EUSOL Biotech Co. Ltd
9. Drug profiles in the detailed report…..
10. Mid-Stage Products (Phase II)
11. MT-3921: Mitsubishi Tanabe Pharma Corporation
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. NVG 291: NervGen Pharma
15. Drug profiles in the detailed report…..
16. Preclinical/Discovery Stage Products
17. Drug Name: Company Name
18. Inactive Products
19. Spinal Cord Injury Key Companies
20. Spinal Cord Injury Key Products
21. Spinal Cord Injury- Unmet Needs
22. Spinal Cord Injury- Market Drivers and Barriers
23. Spinal Cord Injury- Future Perspectives and Conclusion
24. Spinal Cord Injury Analyst Views
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/spinal-cord-injury-pipeline-insight